ibuprofen has been researched along with Birth Weight in 35 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether prophylactic caffeine and ibuprofen, which have been shown to have vascular endothelial growth factor-modulating properties in other contexts, have a detectable effect on the incidence of severe retinopathy of prematurity (ROP) when administered in extremely low birth weight infants during the first 48 hours of life." | 8.02 | The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2021) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 8.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| "To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants." | 7.96 | Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants. ( Chen, X; Huang, Z; Lin, Y; Qiu, X; Sun, P; Walther, FJ; Yang, C, 2020) |
| "Ibuprofen exposure during the first trimester was associated with a decrease in birth weight of 79 grams (95% confidence interval -133 to -25 grams)." | 7.83 | Association of Prenatal Ibuprofen Exposure with Birth Weight and Gestational Age: A Population-Based Sibling Study. ( Nezvalová-Henriksen, K; Nordeng, H; Spigset, O; Wood, M, 2016) |
| "There is a linear relationship between infant birth weight and PDA treatment: the failure rate of a first course of ibuprofen increases with increasing degree of growth restriction." | 7.81 | Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight. ( Aubelle, MS; Gascoin, G; Jarreau, PH; Lopez, E; Madeleneau, D; Patkai, J; Pierron, C; Roze, JC, 2015) |
| "To document trends and covariates of creatinemia (Scr) in extremely low birth weight (ELBW, < 1,000 g) neonates, maternal characteristics [betamethasone, premature preterm rupture of membranes (PPROM), pre-eclampsia, maternal Scr], characteristics at delivery [gestational age (GA), birth weight (BW), small for GA (SGA), Apgar, intubation] and during neonatal stay [ventilation, oxygen, parenteral nutrition, ibuprofen, steroids, intraventricular hemorrhage, retinopathy of prematurity (ROP), phototherapy] were linked with Scr observations." | 7.77 | Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. ( Allegaert, K; George, I; Levtchenko, E; Mekahli, D; Rayyan, M, 2011) |
| "This study aims to determine whether or not treatment of preterm neonates with PDA using IV ibuprofen can impair renal function and in what range of birth weights and gestational ages the risk of major renal side-effects due to ibuprofen is highest." | 5.17 | Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. ( Bagnoli, F; Casucci, M; Messina, G; Mori, A; Rossetti, A; Tomasini, B, 2013) |
| "To determine whether prophylactic caffeine and ibuprofen, which have been shown to have vascular endothelial growth factor-modulating properties in other contexts, have a detectable effect on the incidence of severe retinopathy of prematurity (ROP) when administered in extremely low birth weight infants during the first 48 hours of life." | 4.02 | The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2021) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 4.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| "To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants." | 3.96 | Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants. ( Chen, X; Huang, Z; Lin, Y; Qiu, X; Sun, P; Walther, FJ; Yang, C, 2020) |
| "Ibuprofen exposure during the first trimester was associated with a decrease in birth weight of 79 grams (95% confidence interval -133 to -25 grams)." | 3.83 | Association of Prenatal Ibuprofen Exposure with Birth Weight and Gestational Age: A Population-Based Sibling Study. ( Nezvalová-Henriksen, K; Nordeng, H; Spigset, O; Wood, M, 2016) |
| "There is a linear relationship between infant birth weight and PDA treatment: the failure rate of a first course of ibuprofen increases with increasing degree of growth restriction." | 3.81 | Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight. ( Aubelle, MS; Gascoin, G; Jarreau, PH; Lopez, E; Madeleneau, D; Patkai, J; Pierron, C; Roze, JC, 2015) |
| "To document trends and covariates of creatinemia (Scr) in extremely low birth weight (ELBW, < 1,000 g) neonates, maternal characteristics [betamethasone, premature preterm rupture of membranes (PPROM), pre-eclampsia, maternal Scr], characteristics at delivery [gestational age (GA), birth weight (BW), small for GA (SGA), Apgar, intubation] and during neonatal stay [ventilation, oxygen, parenteral nutrition, ibuprofen, steroids, intraventricular hemorrhage, retinopathy of prematurity (ROP), phototherapy] were linked with Scr observations." | 3.77 | Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. ( Allegaert, K; George, I; Levtchenko, E; Mekahli, D; Rayyan, M, 2011) |
| " Low birth weight, mechanical ventilation, chest tube drainage and ibuprofen therapy are independent risk factors for nosocomial infection in the NICU." | 3.76 | [Investigation of nosocomial infection in the neonatal intensive care unit]. ( Cai, XD; Cao, Y; Chen, C; Ding, H; Wang, CQ; Yang, Y; Zhang, L, 2010) |
| " Target concentration approach by the evaluation of trough level may be applicable to real-time dosing strategy." | 2.78 | The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen. ( Dilmen, U; Erdeve, O; Oncel, MY; Ozdemir, R; Yurttutan, S, 2013) |
| "Ibuprofen levels were detectable 1 h after administration, peaked after 8 h and remained in a relative plateau until 24 h postadministration." | 2.77 | Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. ( Baram, S; Barzilay, B; Batash, D; Berkovitch, M; Goldman, M; Heyman, E; Keidar, R; Youngster, I, 2012) |
| " The template bleeding times before dosing ranged from 135 to 450 s." | 2.74 | Ibuprofen lysine administration to neonates with a patent ductus arteriosus: effect on platelet plug formation assessed by in vivo and in vitro measurements. ( Christensen, RD; Henry, E; Lambert, DK; Schmutz, N; Sheffield, MJ, 2009) |
| " Observations collected in two population pharmacokinetic studies, in preterm neonates, investigating amikacin and vancomycin were used to estimate: i) the impact of ibuprofen administration on the clearance of these drugs; and ii) the difference between prophylactic and therapeutic administration of ibuprofen on this clearance." | 2.72 | Impact of ibuprofen administration on renal drug clearance in the first weeks of life. ( Allegaert, K; Anderson, BJ; Rayyan, M, 2006) |
| "Ibuprofen was not associated with adverse effects." | 2.69 | Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. ( Bertini, G; Dani, C; Fabris, C; Murru, P; Reali, MF; Rubaltelli, FF; Vangi, V, 2000) |
| "Oral ibuprofen for closure of the patent ductus arteriosus failed, and the patient exhibited the features of"ventilator dependent"PDA of premature infants." | 2.53 | [Transcatheter occlusion of patent ductus arteriosus in a preterm infant and review of literatures]. ( Hua, Y; Mu, D; Qiao, L; Shi, X; Tang, J; Wang, X; Wang, Y; Zhou, K, 2016) |
| "Ibuprofen exposure was based on a previously developed population pharmacokinetic study that was in part based on the same study population." | 1.72 | The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants. ( de Klerk, J; Engbers, AGJ; Flint, RB; Goulooze, SC; Knibbe, CAJ; Krekels, EHJ; Reiss, IKM; Simons, SHP; van Dijk, M; Völler, S; Willemsen, SP, 2022) |
| "Ibuprofen (IBU) has been used recently for the treatment of patent ductus arteriosus (PDA) in Japan." | 1.56 | The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants. ( Matsuda, A; Nishizaki, N; Obinata, K; Shimizu, T; Watanabe, A; Yoneyama, T, 2020) |
| "Indomethacin was more efficacious for ductal closure although did not impact outcomes." | 1.42 | Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach. ( Malikiwi, A; Roufaeil, C; Sehgal, A; Tan, K, 2015) |
| "Ibuprofen treatment was given to 15 paracetamol-treated and to 26 control infants (p = 0." | 1.40 | Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants. ( Aikio, O; Hallman, M; Härkin, P; Saarela, T, 2014) |
| "Population pharmacokinetic modelling was performed in nonlinear mixed-effect modelling software (NONMEM version 6." | 1.38 | Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. ( Allegaert, K; Danhof, M; De Cock, RF; de Hoog, M; Knibbe, CA; Schreuder, MF; Sherwin, CM; van den Anker, JN, 2012) |
| "Each ibuprofen-treated infant was matched to two controls." | 1.36 | The renal adverse effects of ibuprofen are not mediated by AQP2 water channels. ( Aperia, A; Hascoët, JM; Vieux, R; Zelenina, M, 2010) |
| "Ibuprofen was administered in a single oral dose of 10 mg/kg between 4 and 72 hours postnatally, and blood samples were collected through an indwelling vascular catheter at time 0 and 1, 2, 4, 8, 12, and 24 hours." | 1.32 | Pharmacokinetics of oral ibuprofen in premature infants. ( Garg, SK; Narang, A; Sharma, PK, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 8 (22.86) | 29.6817 |
| 2010's | 18 (51.43) | 24.3611 |
| 2020's | 8 (22.86) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt-Mehta, V | 1 |
| Schumacher, RE | 1 |
| Engbers, AGJ | 1 |
| Völler, S | 1 |
| Flint, RB | 1 |
| Goulooze, SC | 1 |
| de Klerk, J | 1 |
| Krekels, EHJ | 1 |
| van Dijk, M | 1 |
| Willemsen, SP | 1 |
| Reiss, IKM | 1 |
| Knibbe, CAJ | 1 |
| Simons, SHP | 1 |
| Zhong, B | 1 |
| Tan, K | 2 |
| Razak, A | 1 |
| Sackett, V | 1 |
| Machipisa, C | 1 |
| Zhou, L | 1 |
| Samiee-Zafarghandy, S | 1 |
| Sehgal, A | 2 |
| Hunt, RW | 1 |
| Pharande, P | 1 |
| Malhotra, A | 1 |
| Chen, X | 1 |
| Qiu, X | 1 |
| Sun, P | 1 |
| Lin, Y | 1 |
| Huang, Z | 1 |
| Yang, C | 1 |
| Walther, FJ | 1 |
| Nishizaki, N | 1 |
| Matsuda, A | 1 |
| Yoneyama, T | 1 |
| Watanabe, A | 1 |
| Obinata, K | 1 |
| Shimizu, T | 1 |
| Oh, SH | 1 |
| Lee, BS | 1 |
| Jung, E | 1 |
| Oh, MY | 1 |
| Do, HJ | 1 |
| Kim, EA | 1 |
| Kim, KS | 1 |
| Shen, X | 1 |
| Huang, Y | 1 |
| Guo, H | 1 |
| Peng, H | 1 |
| Yao, S | 1 |
| Zhou, M | 1 |
| Liu, H | 1 |
| Lin, HC | 1 |
| Zhou, P | 1 |
| van Donge, T | 1 |
| Allegaert, K | 5 |
| Gotta, V | 1 |
| Smits, A | 1 |
| Levtchenko, E | 2 |
| Mekahli, D | 2 |
| van den Anker, J | 1 |
| Pfister, M | 1 |
| Kumar, J | 1 |
| Yadav, A | 1 |
| Khuwuthyakorn, V | 1 |
| Tantiprabha, W | 1 |
| Silvilairat, S | 1 |
| Yurttutan, S | 2 |
| Erdeve, O | 2 |
| Oncel, MY | 1 |
| Ozdemir, R | 2 |
| Dilmen, U | 2 |
| Aikio, O | 1 |
| Härkin, P | 1 |
| Saarela, T | 1 |
| Hallman, M | 1 |
| Lee, HC | 1 |
| Durand, DJ | 1 |
| Danielsen, B | 1 |
| Dueñas, GV | 1 |
| Powers, RJ | 1 |
| Malikiwi, A | 1 |
| Roufaeil, C | 1 |
| Madeleneau, D | 1 |
| Aubelle, MS | 1 |
| Pierron, C | 1 |
| Lopez, E | 1 |
| Patkai, J | 1 |
| Roze, JC | 1 |
| Jarreau, PH | 1 |
| Gascoin, G | 1 |
| Lu, D | 1 |
| Liu, Y | 1 |
| Tong, X | 1 |
| Zhou, K | 1 |
| Tang, J | 1 |
| Hua, Y | 1 |
| Shi, X | 1 |
| Wang, Y | 1 |
| Qiao, L | 1 |
| Wang, X | 1 |
| Mu, D | 1 |
| Nezvalová-Henriksen, K | 1 |
| Wood, M | 1 |
| Spigset, O | 1 |
| Nordeng, H | 1 |
| Sheffield, MJ | 1 |
| Schmutz, N | 1 |
| Lambert, DK | 1 |
| Henry, E | 1 |
| Christensen, RD | 1 |
| Vida, VL | 1 |
| Lago, P | 1 |
| Salvatori, S | 1 |
| Boccuzzo, G | 1 |
| Padalino, MA | 1 |
| Milanesi, O | 1 |
| Speggiorin, S | 1 |
| Stellin, G | 1 |
| Cai, XD | 1 |
| Cao, Y | 1 |
| Chen, C | 1 |
| Yang, Y | 1 |
| Wang, CQ | 1 |
| Zhang, L | 1 |
| Ding, H | 1 |
| Vieux, R | 1 |
| Zelenina, M | 1 |
| Aperia, A | 1 |
| Hascoët, JM | 1 |
| George, I | 1 |
| Rayyan, M | 2 |
| Barzilay, B | 1 |
| Youngster, I | 1 |
| Batash, D | 1 |
| Keidar, R | 1 |
| Baram, S | 1 |
| Goldman, M | 1 |
| Berkovitch, M | 1 |
| Heyman, E | 1 |
| Altug, N | 1 |
| Gokmen, T | 1 |
| Oguz, SS | 1 |
| Uras, N | 1 |
| De Cock, RF | 1 |
| Schreuder, MF | 1 |
| Sherwin, CM | 1 |
| de Hoog, M | 1 |
| van den Anker, JN | 1 |
| Danhof, M | 1 |
| Knibbe, CA | 1 |
| Youn, Y | 1 |
| Lee, JY | 2 |
| Lee, JH | 1 |
| Kim, SY | 1 |
| Sung, IK | 1 |
| Bagnoli, F | 1 |
| Rossetti, A | 1 |
| Messina, G | 1 |
| Mori, A | 1 |
| Casucci, M | 1 |
| Tomasini, B | 1 |
| Sharma, PK | 1 |
| Garg, SK | 1 |
| Narang, A | 1 |
| Cappon, GD | 1 |
| Fleeman, TL | 1 |
| Cook, JC | 1 |
| Hurtt, ME | 1 |
| Anderson, BJ | 2 |
| Cossey, V | 1 |
| Holford, NH | 1 |
| Cotton, RB | 1 |
| Dani, C | 1 |
| Bertini, G | 1 |
| Reali, MF | 1 |
| Murru, P | 1 |
| Fabris, C | 1 |
| Vangi, V | 1 |
| Rubaltelli, FF | 1 |
| Hendricks, SK | 1 |
| Smith, JR | 1 |
| Moore, DE | 1 |
| Brown, ZA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Extremely Low Gestational Age Infants' Paracetamol Study: a Randomized Trial[NCT03641209] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2018-09-03 | Active, not recruiting | ||
| Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus of Preterm Infants - Randomised, Placebo-controlled Multicentre Trial[NCT03648437] | Phase 1 | 60 participants (Anticipated) | Interventional | 2018-09-03 | Recruiting | ||
| Prematurity as Predictor of Children's Cardiovascular-renal Health (PREMATCH)[NCT02147457] | 180 participants (Actual) | Observational | 2014-10-31 | Completed | |||
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| Amikacin Pharmacokinetics to Optimize Dosing Recommendations and Patho(Physiological) Considerations in Neonates With Perinatal Asphyxia Treated With Hypothermia[NCT04867993] | 80 participants (Anticipated) | Interventional | 2018-08-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ibuprofen and Birth Weight
| Article | Year |
|---|---|
[Transcatheter occlusion of patent ductus arteriosus in a preterm infant and review of literatures].
Topics: Birth Weight; Body Weight; China; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibupro | 2016 |
7 trials available for ibuprofen and Birth Weight
| Article | Year |
|---|---|
The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen.
Topics: Administration, Oral; Birth Weight; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Fem | 2013 |
Ibuprofen lysine administration to neonates with a patent ductus arteriosus: effect on platelet plug formation assessed by in vivo and in vitro measurements.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Ductus Arteriosus, Patent; Female; Gestationa | 2009 |
Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants.
Topics: Administration, Oral; Birth Weight; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus | 2012 |
Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants.
Topics: Administration, Oral; Birth Weight; Chronic Disease; Cyclooxygenase Inhibitors; Ductus Arteriosus, P | 2012 |
Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns.
Topics: Birth Weight; Blood Urea Nitrogen; Creatinine; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; | 2013 |
Impact of ibuprofen administration on renal drug clearance in the first weeks of life.
Topics: Age Factors; Amikacin; Anti-Bacterial Agents; Aspirin; Betamethasone; Birth Weight; Cyclooxygenase I | 2006 |
Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Apgar Score; Birth Weight; Cyclooxygenase Inhi | 2000 |
27 other studies available for ibuprofen and Birth Weight
| Article | Year |
|---|---|
The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity.
Topics: Birth Weight; Caffeine; Gestational Age; Humans; Ibuprofen; Infant, Newborn; Infant, Very Low Birth | 2021 |
The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants.
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; Infant, Newborn; Infant | 2022 |
Early neurodevelopmental outcomes of extreme preterm infants exposed to paracetamol: a retrospective cohort study.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant; Infant, N | 2023 |
Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Bronchopulmonary Dysplasia; Confounding Facto | 2020 |
The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Case-Control Studies; Ductus Arteriosus, Pate | 2020 |
Plasma B-type natriuretic peptide cannot predict treatment response to ibuprofen in preterm infants with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Birth Weight; Ductus Arteriosus, Patent; Female | 2020 |
Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
Topics: Birth Weight; Cholestasis; Ductus Arteriosus, Patent; Emulsions; Humans; Ibuprofen; Indomethacin; In | 2021 |
Characterizing dynamics of serum creatinine and creatinine clearance in extremely low birth weight neonates during the first 6 weeks of life.
Topics: Birth Weight; Creatinine; Humans; Ibuprofen; Infant, Extremely Low Birth Weight; Infant, Newborn; Ki | 2021 |
Comparison of efficacy and safety of oral ibuprofen versus oral indomethacin.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, V | 2019 |
Reply to letter to the editor: Comparison of efficacy and safety of oral ibuprofen versus oral indomethacin.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, V | 2019 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Early paracetamol treatment associated with lowered risk of persistent ductus arteriosus in very preterm infants.
Topics: Acetaminophen; Birth Weight; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; | 2014 |
Hospital variation in medical and surgical treatment of patent ductus arteriosus.
Topics: Birth Weight; California; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational | 2015 |
Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Creatinine; Ductus Arteriosus, Patent; Female | 2015 |
Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight.
Topics: Age Factors; Birth Weight; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational | 2015 |
[Clinical characteristics and cardiac hemodynamic changes of patent ductus ateriosus in preterm infants].
Topics: Birth Weight; Bronchopulmonary Dysplasia; Cardiac Output; Cyclooxygenase Inhibitors; Ductus Arterios | 2015 |
Association of Prenatal Ibuprofen Exposure with Birth Weight and Gestational Age: A Population-Based Sibling Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Child; Female; Gestational Age; Humans | 2016 |
Is there an optimal timing for surgical ligation of patent ductus arteriosus in preterm infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apgar Score; Birth Weight; Ductus Arteriosus, Patent; Femal | 2009 |
[Investigation of nosocomial infection in the neonatal intensive care unit].
Topics: Birth Weight; Chest Tubes; Cross Infection; Female; Humans; Ibuprofen; Incidence; Infant, Newborn; I | 2010 |
The renal adverse effects of ibuprofen are not mediated by AQP2 water channels.
Topics: Analgesics, Non-Narcotic; Aquaporin 2; Birth Weight; Female; Gestational Age; Glomerular Filtration | 2010 |
Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates.
Topics: Adult; Aging; Anti-Inflammatory Agents, Non-Steroidal; Apgar Score; Birth Weight; Cohort Studies; Cr | 2011 |
Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance.
Topics: Age Factors; Amikacin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; | 2012 |
Impact of patient selection on outcomes of PDA in very low birth weight infants.
Topics: Administration, Oral; Birth Weight; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational | 2013 |
Pharmacokinetics of oral ibuprofen in premature infants.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Chromatography, High Pr | 2003 |
Combined treatment potentiates the developmental toxicity of ibuprofen and acetazolamide in rats.
Topics: Abnormalities, Drug-Induced; Acetazolamide; Animals; Animals, Newborn; Birth Weight; Body Weight; Ca | 2005 |
Limited predictability of amikacin clearance in extreme premature neonates at birth.
Topics: Age Factors; Amikacin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bact | 2006 |
Don't discard your indomethacin yet.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Brain; Cerebral Hemorrhage; Clinical Trials a | 2000 |
Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour.
Topics: Adult; Amniotic Fluid; Birth Weight; Female; Gestational Age; Humans; Ibuprofen; Indomethacin; Infan | 1990 |